Marksans Pharma is pushing deeper into big, tightly regulated markets where demand for lower-cost medicines keeps rising, and it’s boosting production so it can ship more without ramping costs as fast. The upside hinges on new approvals and a better mix of higher-value products, but heavy competition, pricing pressure in key markets, and regulatory surprises could derail the story.Read more

₹266

7.2% undervalued

AnalystConsensusTarget's

Fair Value

Revenue

15.78% p.a.

Profit Margin

16.79%

Future PE

22.42x

Price in 2029

₹378.23

Marksans Pharma

Rising North America Dependence And Overextended Pipeline Will Pressure Margins And Earnings

Marksans Pharma is leaning more heavily on North America while also pushing a very crowded wave of new product filings across several countries, and that mix could squeeze profits if pricing gets tougher. See why its big growth plans could strain spending and supply chains, even as the company tries to use its unused factory capacity to expand.Read more

₹210

17.6% overvalued

AnalystLowTarget's

Fair Value

Revenue

16.42% p.a.

Profit Margin

16.87%

Future PE

17.35x

Price in 2029

₹299.12

Trending Discussion

Snowflake Analysis

Flawless balance sheet average dividend payer.

1 Risk

4 Rewards

View Full Analysis

Marksans Pharma Limited Key Details

Last Reported Earnings

Mar 31, 2026

Next Reporting Earnings

n/a

: 9.22
: 56.72%
: 14.16%
: 1.0%

View Full Analysis

About MARKSANS

Founded: 1992
Employees: 1840
CEO: Mark Saldanha
WebsiteView website: marksanspharma.com

Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamines, anti-fungal, anti-viral, laxatives, and cold and cough therapeutic areas. Its product portfolio includes plain, enteric-coated, and film coated tablets; soft gelatin and hard capsules; oral liquids; and ointments, as well as creams and liquids. The company provides its products to supermarkets, high street retailers, pharmacy chains, and wholesalers. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.